Quesada J R, Gutterman J U
J Natl Cancer Inst. 1983 Jun;70(6):1041-6.
The effects of recombinant DNA-produced leukocyte interferon (IFLrA) were studied in 37 patients with metastatic cancer who received sequentially escalating doses of 9-86 million units (MU) of IFLrA by im injection twice weekly. The IFLrA was absorbed rapidly and reached a peak serum concentration 6-8 hours after injection. Serum concentration of IFLrA increased proportionately with the dose. The most common side effects included fever, chills, asthenia, anorexia, and weight loss, and leukopenia, granulocytopenia, and lymphopenia occurred frequently. Elevation of serum glutamic-oxaloacetic transaminase was frequent above doses of 50 MU. All side effects were reversible by discontinuation of the drug. Antibodies to IFLrA were detected in 3 patients while on treatment. The presence of antibodies coincided with drastic reduction in serum IFLrA concentration and, in 1 patient, with relapse of disease. Objective tumor responses were documented in patients with lymphomas but not in other groups of patients.
对37例转移性癌症患者进行了研究，这些患者每周两次通过肌肉注射依次递增剂量（900 - 8600万单位）的重组DNA产生的白细胞干扰素（IFLrA）。IFLrA吸收迅速，注射后6 - 8小时达到血清峰值浓度。IFLrA的血清浓度随剂量成比例增加。最常见的副作用包括发热、寒战、乏力、厌食和体重减轻，白细胞减少、粒细胞减少和淋巴细胞减少也频繁发生。血清谷草转氨酶在剂量超过5000万单位时经常升高。所有副作用在停药后均可逆转。治疗期间在3例患者中检测到了针对IFLrA的抗体。抗体的出现与血清IFLrA浓度急剧下降同时发生，在1例患者中还与疾病复发同时出现。淋巴瘤患者有客观肿瘤反应记录，但其他患者组未出现。
